Certara Sells Business to Focus on Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy CERT?
Source: seekingalpha
- Significant Transaction Value: Certara announced the sale of its regulatory and medical writing business to contract research organization Veristat for up to $135 million, enabling the company to focus on its model-informed drug development and clinical intelligence solutions.
- Revenue and Profitability: The unit generated $50 million in revenue and $17 million in adjusted EBITDA last year, demonstrating its profitability in the market while providing Certara with substantial funding support.
- Strategic Shift: CEO Jon Resnick stated that this transaction underscores the company's commitment to accelerating AI-integrated modeling and simulation across the drug development lifecycle, indicating a further push towards technological innovation.
- Future Outlook Adjustment: Certara plans to revise its full-year outlook once the deal finalizes in Q2 2026, with intentions to deploy the proceeds to drive long-term value for customers, patients, and shareholders, thereby strengthening its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CERT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CERT
Wall Street analysts forecast CERT stock price to rise
11 Analyst Rating
7 Buy
4 Hold
0 Sell
Moderate Buy
Current: 6.310
Low
9.00
Averages
12.11
High
16.00
Current: 6.310
Low
9.00
Averages
12.11
High
16.00
About CERT
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Certara to Announce Q1 Earnings on May 11
- Earnings Announcement: Certara (CERT) is set to announce its Q1 2023 earnings on May 11 before market open, with consensus EPS estimate at $0.11, reflecting a 21.4% year-over-year decline, and revenue estimate at $106.1 million, indicating a modest 0.1% year-over-year growth.
- Performance Expectations: Over the past two years, Certara has exceeded EPS estimates 63% of the time and revenue estimates 75% of the time, indicating a relatively stable performance in meeting market expectations.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with 9 downward adjustments, while revenue estimates also saw no upward revisions and 8 downward adjustments, suggesting a cautious market outlook for Certara's future performance.
- Strategic Overhaul: The new CEO has indicated an operational overhaul, with plans to sell the regulatory and medical writing business for up to $135 million, while projecting revenue growth to remain flat to 4% by 2026, highlighting a strategic pivot in response to market conditions.
See More
On-Demand Access to Precious Metals & Critical Minerals Virtual Investor Conference Presentations
- Conference Content Replay: Presentations from the Precious Metals & Critical Minerals Virtual Investor Conference are now available for on-demand viewing, allowing investors, advisors, and analysts to access content 24/7 for 90 days, thereby enhancing convenience and flexibility in information retrieval.
- One-on-One Meeting Arrangements: Selected companies are accepting requests for one-on-one management meetings, enabling investors to communicate directly with company leadership, which enhances interaction and transparency between investors and companies.
- Resource Download Convenience: Attendees can download investor materials from the company's resource section, which not only provides comprehensive information support for investors but also promotes a deeper understanding of the company's business.
- Advantages of Virtual Conferences: Virtual Investor Conferences offer real-time investor engagement solutions that improve the efficiency of connections between companies and investors, marking a new trend in investor relations management, especially among retail and institutional investors globally.
See More
Precious Metals & Critical Minerals Virtual Investor Conference Announced
- Conference Agenda Released: The Precious Metals & Critical Minerals Virtual Investor Conference is set for May 5-7, 2026, attracting individual and institutional investors, which is expected to enhance market attention on the sector due to strong investor interest.
- Ease of Participation: Investors can register for free and attend the conference, with system checks designed to expedite participation and ensure timely updates, thereby increasing engagement and interaction during the event.
- Diverse Company Presentations: The conference will feature multiple companies, including Novo Resources Corp. and Atlas Lithium Corp., providing investors with a wealth of investment opportunities that could further drive capital inflow into the precious metals and critical minerals sectors.
- Enhanced Investor Interaction: The virtual format offers a real-time interactive platform for companies to hold one-on-one meetings with investors, improving the efficiency of investor relations management and facilitating direct communication between companies and potential investors.
See More
Certara Sells Business to Focus on Drug Development
- Significant Transaction Value: Certara announced the sale of its regulatory and medical writing business to contract research organization Veristat for up to $135 million, enabling the company to focus on its model-informed drug development and clinical intelligence solutions.
- Revenue and Profitability: The unit generated $50 million in revenue and $17 million in adjusted EBITDA last year, demonstrating its profitability in the market while providing Certara with substantial funding support.
- Strategic Shift: CEO Jon Resnick stated that this transaction underscores the company's commitment to accelerating AI-integrated modeling and simulation across the drug development lifecycle, indicating a further push towards technological innovation.
- Future Outlook Adjustment: Certara plans to revise its full-year outlook once the deal finalizes in Q2 2026, with intentions to deploy the proceeds to drive long-term value for customers, patients, and shareholders, thereby strengthening its market position.
See More
Certara to Participate in Multiple Investor Conferences
- Investor Conference Schedule: Certara will participate in three significant healthcare investor conferences on March 3, 9, and 10, 2026, showcasing its leadership in drug development.
- Timing Details: The TD Cowen conference is set for March 3 at 3:10 PM, the Leerink conference on March 9 at 8:00 AM, and the Barclays conference on March 10 at 1:00 PM, ensuring timely updates for investors.
- Webcast Availability: Each conference will feature live webcasts accessible via Certara's investor relations website, with replays available for at least 90 days post-event, enhancing information accessibility for stakeholders.
- Extensive Client Base: Certara serves over 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries, highlighting its significant influence and demand in the global drug development landscape.
See More
Certara, Inc. Q4 2025 Earnings Call Insights
- Revenue Growth: Certara reported total revenue of $103.6 million for Q4 2025, reflecting a 3% year-over-year increase, demonstrating the company's stability and potential growth opportunities in the life sciences sector despite market challenges.
- Adjusted EBITDA: The adjusted EBITDA for Q4 was $32.5 million, down from $33.5 million in Q4 2024, highlighting the urgency and necessity for the company to enhance operational efficiency.
- Strategic Priorities: New CEO Jon Resnick emphasized three strategic priorities, including focusing on the product portfolio, deepening customer engagement, and raising operational standards, aiming to drive future growth through AI-driven efficiencies.
- Future Outlook: Certara projects total revenue for 2026 to be flat to 4% growth, with management acknowledging that this year will be a transition period, planning to reinvigorate growth and enhance shareholder value through cost control and innovation.
See More
Certara to Announce Q1 Earnings on May 11
- Earnings Announcement: Certara (CERT) is set to announce its Q1 2023 earnings on May 11 before market open, with consensus EPS estimate at $0.11, reflecting a 21.4% year-over-year decline, and revenue estimate at $106.1 million, indicating a modest 0.1% year-over-year growth.
- Performance Expectations: Over the past two years, Certara has exceeded EPS estimates 63% of the time and revenue estimates 75% of the time, indicating a relatively stable performance in meeting market expectations.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with 9 downward adjustments, while revenue estimates also saw no upward revisions and 8 downward adjustments, suggesting a cautious market outlook for Certara's future performance.
- Strategic Overhaul: The new CEO has indicated an operational overhaul, with plans to sell the regulatory and medical writing business for up to $135 million, while projecting revenue growth to remain flat to 4% by 2026, highlighting a strategic pivot in response to market conditions.
See More
On-Demand Access to Precious Metals & Critical Minerals Virtual Investor Conference Presentations
- Conference Content Replay: Presentations from the Precious Metals & Critical Minerals Virtual Investor Conference are now available for on-demand viewing, allowing investors, advisors, and analysts to access content 24/7 for 90 days, thereby enhancing convenience and flexibility in information retrieval.
- One-on-One Meeting Arrangements: Selected companies are accepting requests for one-on-one management meetings, enabling investors to communicate directly with company leadership, which enhances interaction and transparency between investors and companies.
- Resource Download Convenience: Attendees can download investor materials from the company's resource section, which not only provides comprehensive information support for investors but also promotes a deeper understanding of the company's business.
- Advantages of Virtual Conferences: Virtual Investor Conferences offer real-time investor engagement solutions that improve the efficiency of connections between companies and investors, marking a new trend in investor relations management, especially among retail and institutional investors globally.
See More
Precious Metals & Critical Minerals Virtual Investor Conference Announced
- Conference Agenda Released: The Precious Metals & Critical Minerals Virtual Investor Conference is set for May 5-7, 2026, attracting individual and institutional investors, which is expected to enhance market attention on the sector due to strong investor interest.
- Ease of Participation: Investors can register for free and attend the conference, with system checks designed to expedite participation and ensure timely updates, thereby increasing engagement and interaction during the event.
- Diverse Company Presentations: The conference will feature multiple companies, including Novo Resources Corp. and Atlas Lithium Corp., providing investors with a wealth of investment opportunities that could further drive capital inflow into the precious metals and critical minerals sectors.
- Enhanced Investor Interaction: The virtual format offers a real-time interactive platform for companies to hold one-on-one meetings with investors, improving the efficiency of investor relations management and facilitating direct communication between companies and potential investors.
See More
Certara Sells Business to Focus on Drug Development
- Significant Transaction Value: Certara announced the sale of its regulatory and medical writing business to contract research organization Veristat for up to $135 million, enabling the company to focus on its model-informed drug development and clinical intelligence solutions.
- Revenue and Profitability: The unit generated $50 million in revenue and $17 million in adjusted EBITDA last year, demonstrating its profitability in the market while providing Certara with substantial funding support.
- Strategic Shift: CEO Jon Resnick stated that this transaction underscores the company's commitment to accelerating AI-integrated modeling and simulation across the drug development lifecycle, indicating a further push towards technological innovation.
- Future Outlook Adjustment: Certara plans to revise its full-year outlook once the deal finalizes in Q2 2026, with intentions to deploy the proceeds to drive long-term value for customers, patients, and shareholders, thereby strengthening its market position.
See More
Certara to Participate in Multiple Investor Conferences
- Investor Conference Schedule: Certara will participate in three significant healthcare investor conferences on March 3, 9, and 10, 2026, showcasing its leadership in drug development.
- Timing Details: The TD Cowen conference is set for March 3 at 3:10 PM, the Leerink conference on March 9 at 8:00 AM, and the Barclays conference on March 10 at 1:00 PM, ensuring timely updates for investors.
- Webcast Availability: Each conference will feature live webcasts accessible via Certara's investor relations website, with replays available for at least 90 days post-event, enhancing information accessibility for stakeholders.
- Extensive Client Base: Certara serves over 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries, highlighting its significant influence and demand in the global drug development landscape.
See More
Certara, Inc. Q4 2025 Earnings Call Insights
- Revenue Growth: Certara reported total revenue of $103.6 million for Q4 2025, reflecting a 3% year-over-year increase, demonstrating the company's stability and potential growth opportunities in the life sciences sector despite market challenges.
- Adjusted EBITDA: The adjusted EBITDA for Q4 was $32.5 million, down from $33.5 million in Q4 2024, highlighting the urgency and necessity for the company to enhance operational efficiency.
- Strategic Priorities: New CEO Jon Resnick emphasized three strategic priorities, including focusing on the product portfolio, deepening customer engagement, and raising operational standards, aiming to drive future growth through AI-driven efficiencies.
- Future Outlook: Certara projects total revenue for 2026 to be flat to 4% growth, with management acknowledging that this year will be a transition period, planning to reinvigorate growth and enhance shareholder value through cost control and innovation.
See More
